Posted on November 29, 2009 by jmmeijer
Understanding how a medical professional goes about their business on a day to day basis gives a product development engineer the type of base knowledge that can be built upon to gain a solid appreciation for their needs. The Howard Hughes Medical Institute has a number of interactive labs that could serve that purpose. This type of knowledge would be useful for a fledgling engineer to get a deeper insight into the general process used to diagnose and treat patients. It should be noted that the patient interview, observation and reaction to a doctor’s first hand manipulations ( chest thump, reflex test, flexion of limbs, etc. ) are the initial and many times the only information the doctor needs to make a diagnosis. The high technology diagnostic equipment comes into play only after the doctor gets stumped or wants to verify the diagnosis for medical or legal reasons ( defensive medicine ). The following link allows the engineer to walk through some of a doctor’s diagnostic process when cardiovascular disease is suspected.
HHMI Virtual Cardiology Laboratory

Filed under: BMET Faculty, Bioengineering Curriculum, Biomedical Engineering Faculty | Tagged: Biomedical Engineering Curriculum, Biomedical Engineering Preparation, Biomedical Engineering Technology Curriculum | Leave a Comment »
Posted on November 22, 2009 by jmmeijer
There are any number of reasons why these are small graduating classes. The most likely is that the listed schools have only recently inaugurated their Biomedical Engineering programs. A number of schools took advantage of the Biomedical Engineering program grants by the now defunct Whitaker Foundation before it ceased to exist in 2005. The foundation supported the creation of at least 30 programs. Personally I don’t believe that a small graduating class has anything to do with the quality of a program. It would be wise for prospective students and their parents to ask about plans for accreditation at these schools.
| School |
Male |
Female |
Total |
| George Washington University |
9 |
7 |
16 |
| Milwaukee School of Engineering |
9 |
6 |
15 |
| Wright State University-Main Campus |
9 |
5 |
14 |
| Bucknell University |
6 |
8 |
14 |
| Catholic University of America |
8 |
4 |
12 |
| Oregon State University |
5 |
6 |
11 |
| University of Nebraska-Lincoln |
6 |
5 |
11 |
| University of Akron Main Campus |
6 |
4 |
10 |
| University of the Pacific |
6 |
2 |
8 |
| Western New England College |
3 |
5 |
8 |
| Alfred University |
2 |
5 |
7 |
| LeTourneau University |
3 |
3 |
6 |
| University of Central Oklahoma |
4 |
2 |
6 |
| Washington State University |
4 |
2 |
6 |
| University of California-Riverside |
3 |
3 |
6 |
| Indiana University-Purdue University-Indianapolis |
2 |
4 |
6 |
| University of Houston |
5 |
1 |
6 |
| California Polytechnic State University-San Luis Obispo |
3 |
2 |
5 |
| The College of New Jersey |
3 |
2 |
5 |
| University of Idaho |
1 |
0 |
1 |

Filed under: Bioengineering Jobs, Career Related Data, Colleges and Universities | Tagged: Biomedical Engineering Colleges, Biomedical Engineering Schools | Leave a Comment »
Posted on November 20, 2009 by jmmeijer
Blood substitutes have been part of artificial organ research for a number of years. They came in many forms. Some of the early blood substitutes were fluorocarbon based. Many were hemoglobin based as are all of the major contenders today. I started working on blood substitutes around 1978 at Michael Reese as a Research Assistant working with Dr. Moss’ group. Dr. Moss went on to create Northfield Corporation. We parted company when he decided not to support liposome encapsulated hemoglobin research in his lab. I continued to work on LEH for my dissertation at Rush Presbyterian St. Lukes Medical Center under the auspices of the Department of Anesthesiology. I created a more commercially viable production technique and performed a number of experiments on rabbits, and rats to prove its efficacy. Baxter supported the research and ultimately modified the process I created. They were not unfortunately able to commercialize it for a number of reasons. Besides technical issues the chief reason was the discovery of HIV. There were no reliable tests at the time and my impression is that the risks were deemed to high to proceed.
In restrospect LEH blood substitutes could be considered one of the early pioneering attempts to develop biologically based pharmaceuticals. It involved separation of the cytosol from the cell membrane by a series of chemical, centrifugation and cross flow filtration techniques. Before it was encapsulated the hemoglobin rich cytosol was augmented with nutrients and cofactors to extend its shelf and circulating life.
Now it appears that hemoglobin based blood substitutes are at a cross roads. With the advent of adult stem cell research and hobbled by a number of negative trials this approach appears to be headed for the history books.
Blood Not So Simple: Controversial Hemoglobin Substitutes on Life Support

Filed under: Biomedical Product Development | Leave a Comment »
Posted on November 17, 2009 by jmmeijer
Posted on November 14, 2009 by jmmeijer